JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 1, 2008; DOI: 10.1124/jpet.108.139659


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.139659v1
327/1/130    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Matsuda, T.
Right arrow Articles by Yanagihara, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsuda, T.
Right arrow Articles by Yanagihara, N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*HISTAMINE
*SODIUM


Received for publication April 2, 2008.
Revised June 27, 2008.
Accepted for publication June 30, 2008.

Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na+ and Ca2+ influx in bovine adrenal medullary cells

Taeko Matsuda 1, Yumiko Toyohira 1, Susumu Ueno 1, Masato Tsutsui 1, Nobuyuki Yanagihara 2*

1 Department of Pharmacology, University of Occupational & Environmental Health, School of Medicine 2 University of Occupational & Env. Health

* Address correspondence to: E-mail: yanagin{at}med.uoeh-u.ac.jp

Abstract

Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is a potent inhibitor of cholesterol biosynthesis and has beneficial effects in the primary and secondary prevention of cardiovascular diseases. Here, we report the effects of simvastatin on catecholamine secretion and synthesis in cultured bovine adrenal medullary cells used as a model of sympathetic neurons. Simvastatin inhibited catecholamine secretion induced by acetylcholine, an agonist of the nicotinic acetylcholine receptor, by veratridine, an activator of voltage-dependent Na+ channels, and by high K+, an activator of voltage-dependent Ca2+ channels (IC50=3.8, 7.8, and 6.1 µM, respectively). Simvastatin also suppressed acetylcholine-induced 22Na+ influx (IC50=4.3 µM) and 45Ca2+ influx (IC50=6.1 µM), veratridine-induced 22Na+ influx (IC50=6.6 µM) and 45Ca2+ influx (IC50=12 µM), and high K+-induced 45Ca2+ influx (IC50=11 µM). The reduction of catecholamine secretion caused by simvastatin was not overcome by increasing the concentration of acetylcholine or by treatment with mevalonate, the first metabolite of HMG-CoA. The inhibitory effect of simvastatin on histamine-induced secretion of catecholamines was observed in the presence of extracellular Ca2+, but not in a Ca2+-free medium, suggesting that simvastatin does not interfere with histamine receptors non-selectively. Simvastatin also suppressed acetylcholine-induced 14C-catecholamine synthesis from [14C]tyrosine as well as tyrosine hydroxylase activity. These findings suggest that simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine through suppression of Na+ and Ca2+ influx in the adrenal medulla and probably in the sympathetic neurons.


Key words: Adrenal medulla, Cattecholamine, Nicotinic acetylcholine receptor, Secretion, Simvastatin, Synthesis





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.